Caribou Biosciences shares jump 11.05% intraday after FDA grants RMAT designation for CB-011 in r/r multiple myeloma.

Caribou Biosciences surged 11.05% intraday, following the announcement that the FDA has granted RMAT (Regenerative Medicine Advanced Therapy) designation to its allogeneic anti-BCMA CAR-T cell therapy, CB-011, for the treatment of relapsed/refractory multiple myeloma. The RMAT designation is based on early clinical data showing a 92% overall response rate, 75% with at least complete response, and 91% minimal residual disease negativity in 12 treatment-naïve r/r MM patients.